BridgeBio Pharma (BBIO) director sells 17167.0000 shares after option exercise

Rhea-AI Filing Summary

BridgeBio Pharma director Andrea Ellis reported an exercise-and-sale sequence involving 17167.0000 shares of common stock on July 9, 2026. She exercised stock options to acquire 17167.0000 shares at 16.7500 per share and sold 17167.0000 shares at 84.0000 per share in an open-market transaction pursuant to a Rule 10b5-1 sales plan adopted on December 3, 2025. The sale transaction line reports 22579.0000 common shares beneficially owned directly immediately following that sale.

Filing Explained

As of July 9, the director held 22,579 direct shares after selling 17,167 exercised shares; the remaining option covers 17,167 shares through June 21, 2033.

The July 9, 2026 filing records completed transactions by a director: an option exercise acquiring 17,167 common shares and a sale disposing of 17,167 common shares.

After the reported transactions, the table shows 22,579 directly held common shares and an option covering 17,167 common shares.

The filing says the sale was effected under a Rule 10b5-1 sales plan adopted on December 3, 2025.

Under the supplied definitions, code M identifies an option or derivative exercise, code S identifies an open-market sale, and a Rule 10b5-1 plan is written in advance to execute trades under a schedule or formula; the filing gives the plan's adoption date, not reasons for the individual trade.

The exercise price was $16.75, while the reported sale price was $84 per share.

The remaining option is listed as exercisable through June 21, 2026 and expiring on June 21, 2033.

Insider Trade Summary 10b5-1

Net Seller: 17,167 shares ($1,442,028)

Net Sell 3 txns

Insider Ellis Andrea

Role Director

Sold 17,167 shs ($1.44M)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	17,167	$0.00	--
Exercise	Common Stock	17,167	$16.75	$288K
Sale	Common Stock	17,167	$84.00	$1.44M

Holdings After Transaction: Stock Option (right to buy) — 17,167 shares (Direct); Common Stock — 39,746 shares (Direct)

Footnotes (1)

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2025. 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.

Key Figures

Shares sold: 17167.0000 shares Sale price per share: 84.0000 per share Options exercised: 17167.0000 shares +4 more

7 metrics

Shares sold 17167.0000 shares Common stock sold in open-market transaction on 2026-07-09

Sale price per share 84.0000 per share Price received for the 17167.0000 common shares sold

Options exercised 17167.0000 shares Common shares acquired through option exercise on 2026-07-09

Exercise price per share 16.7500 per share Exercise price of the stock option converted into common stock

Common shares after sale 22579.0000 shares Common stock beneficially owned directly following the reported sale transaction

Stock option expiration date 2033-06-21 Expiration date of the stock option covering 17167.0000 underlying shares

Rule 10b5-1 plan adoption date December 3, 2025 Date the Rule 10b5-1 sales plan governing the reported sale was adopted

Key Terms

Rule 10b5-1 sales plan, Stock Option (right to buy), derivative security, open-market sale

4 terms

Rule 10b5-1 sales plan regulatory

"This transaction was effected pursuant to a Rule 10b5-1 sales plan"

Stock Option (right to buy) financial

"Stock Option (right to buy) with underlying common stock shares"

derivative security financial

"Exercise or conversion of derivative security reported with code M"

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

open-market sale financial

"Sale in open market or private transaction of common stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/13/2026 - 04:42 PM Accepted by SEC EDGAR 07/13/2026 - 04:41 PM Learn about SEC filing dates

FAQ

What insider trading activity did BridgeBio Pharma (BBIO) director Andrea Ellis report?

Andrea Ellis reported exercising options for 17167.0000 shares of BridgeBio common stock and selling 17167.0000 shares in an open-market transaction on July 9, 2026. The filing describes this as an exercise-and-sale pattern in common stock and related stock options.

How many BridgeBio Pharma (BBIO) shares did Andrea Ellis sell and at what price?

Ellis sold 17167.0000 shares of BridgeBio common stock at 84.0000 per share in an open-market or private transaction. This disposition was reported as a non-derivative transaction coded “S” for sale on July 9, 2026.

What stock options did Andrea Ellis exercise in the BridgeBio Pharma (BBIO) Form 4?

Ellis exercised stock options covering 17167.0000 shares of BridgeBio common stock at an exercise price of 16.7500 per share. The derivative position is reported as a “Stock Option (right to buy)” with an expiration date of 2033-06-21.

Was Andrea Ellis’s BridgeBio Pharma (BBIO) share sale under a Rule 10b5-1 plan?

Yes. A footnote states the sale was effected pursuant to a Rule 10b5-1 sales plan adopted by Ellis on December 3, 2025. Such pre-arranged plans automate trading and can reduce the informational value of trade timing.

How many BridgeBio Pharma (BBIO) shares does Andrea Ellis report owning after the sale transaction?

The sale transaction line reports Ellis beneficially owning 22579.0000 shares of BridgeBio common stock directly immediately following that sale. This figure reflects her reported direct common stock holdings on that specific transaction line.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ellis Andrea

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/09/2026		M(1)		17,167	A	$16.75	39,746	D
Common Stock	07/09/2026		S(1)		17,167	D	$84	22,579	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$16.75	07/09/2026		M(1)			17,167	(2)	06/21/2033	Common Stock	17,167	$0	17,167	D

Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2025.

2. 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.

Remarks:

	/s/ Will Solis, Attorney-in-Fact	07/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)